Advanced Malignancies Clinical Trials

A listing of Advanced Malignancies medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 96 clinical trials
Neratinib + Valproate in Advanced Solid Tumors w/Expansion Cohort in Ras-Mutated Ca

To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors. Then to explore the antitumor effects of the neratinib and sodium valproate combination in advanced solid tumors with attention to RAS-mutated tumors, EGFR-altered GBM, and ocular …

metastasis
cancer
solid tumour
alopecia
neratinib
  • 14 views
  • 09 Sep, 2021
  • 1 location
A Dose-escalation Expansion Study of ARX788 in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.

erbb2
solid tumour
measurable disease
doxorubicin
renal function
  • 16 views
  • 08 Sep, 2021
  • 9 locations
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1

cancer
  • 0 views
  • 17 Sep, 2021
  • 8 locations
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

platelet count
erbb2
solid tumour
palb2
triple-negative breast cancer
  • 5 views
  • 08 Sep, 2021
  • 1 location
A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.

solid tumour
  • 2 views
  • 11 Sep, 2021
  • 3 locations
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2 PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, …

  • 1 views
  • 19 Sep, 2021
  • 2 locations
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Percutaneously Accessible Advanced Solid Tumors (ATLAS-IT-05)

ATLAS-IT-05 is an open-label, single-arm study in patients with superficial advanced solid tumors accessible for injection (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who have either exhausted treatment options or are not eligible for, suitable for, or willing to undergo such treatments.

  • 0 views
  • 12 Sep, 2021
  • 1 location
Study of RP-6306 in Advanced Solid Tumors

The primary purpose of this study is to assess the safety and tolerability of RP-6306 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

  • 0 views
  • 19 Sep, 2021
Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies

This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled design. The study is comprised of two parts: Part A (single-agent dose escalation) and Part B (single-agent expansion cohorts).

platelet count
beta human chorionic gonadotropin
large b-cell lymphoma
measurable disease
neutrophil count
  • 0 views
  • 20 Sep, 2021
  • 2 locations
Lurbinectedin With Berzosertib an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Background Small cell lung cancer (SCLC) and high-grade neuroendocrine cancers (HGNEC) are aggressive neuroendocrine cancers. At first, SCLC and HGNEC respond to chemotherapy. But then they relapse quickly and become resistant to treatment. Researchers want to see if a combination of drugs can help. Objective To see if the combination …

lurbinectedin
ATR
measurable disease
neutrophil count
cancer chemotherapy
  • 0 views
  • 12 Sep, 2021
  • 1 location